Welcome to our dedicated page for Mural Oncology PLC news (Ticker: MURA), a resource for investors and traders seeking the latest updates and insights on Mural Oncology PLC stock.
Mural Oncology PLC (MURA) is a clinical-stage biotech company pioneering engineered cytokine therapies for cancer treatment. This page aggregates official announcements, clinical trial updates, and strategic developments related to their innovative immuno-oncology pipeline.
Investors and researchers will find timely updates on key programs including nemvaleukin (IL-2 fusion protein), IL-18, and IL-12 therapies. Content spans regulatory milestones, partnership announcements, financial disclosures, and scientific presentations - all essential for understanding the company's progress in redefining cytokine-based cancer treatments.
Our curated news collection enables efficient tracking of material events including clinical trial initiations, data readouts, and intellectual property developments. The resource is particularly valuable for monitoring advancements in protein-engineered therapies designed to enhance antitumor immunity while reducing systemic toxicity.
Bookmark this page for consolidated access to Mural Oncology's latest developments in immuno-oncology research and clinical translation. Check regularly for updates on novel therapeutic approaches that combine cytokine biology with precision engineering.
Mural Oncology plc (Nasdaq: MURA) has appointed George Golumbeski, Ph.D., to its board of directors effective July 30, 2024. Dr. Golumbeski brings 30 years of leadership in business development, with extensive experience in strategic collaborations, M&A, licensing, and alliance management. He currently serves as a partner at DROIA Ventures and has held key positions at GRAIL, Celgene, Nabriva Therapeutics, Novartis Oncology, and Elan Biopharmaceuticals.
Mural Oncology, a clinical-stage immuno-oncology company, is developing engineered cytokine therapies for cancer treatment. The company has two potentially registrational studies reading out in the first half of 2025 and two preclinical programs approaching candidate nomination later this year. Dr. Golumbeski's appointment is expected to bring valuable expertise as Mural advances its current programs and explores potential partnerships.
Mural Oncology, a clinical-stage immuno-oncology company, announced on July 1, 2024, the granting of non-statutory stock options and restricted stock units under its 2024 Inducement Stock Option and Incentive Plan. The grants were made as inducements for four newly hired employees under Nasdaq Listing Rule 5635(c)(4). The stock options cover 15,470 ordinary shares at an exercise price of $3.11, with a ten-year term and a vesting schedule of four years. The restricted stock units cover 8,330 ordinary shares, also vesting over four years. Both grants are subject to the terms of respective award agreements and the company's 2024 Inducement Plan.
Mural Oncology (Nasdaq: MURA), a clinical-stage immuno-oncology company, announced that CEO Caroline Loew, Ph.D., will present at the 14th Annual East Coast IDEAS Investor Conference on June 13 at 9:15 a.m. EST.
The company focuses on developing engineered cytokine therapies to address unmet needs in cancer treatment. A webcast of the presentation will be available at www.threepartadvisors.com/east-coast and ir.muraloncology.com.
Mural will also host one-on-one investor meetings during the conference.
Mural Oncology, a clinical-stage immuno-oncology company listed on Nasdaq under the ticker MURA, announced the granting of inducement stock options and restricted stock units to two new employees.
On June 3, 2024, the company awarded non-statutory stock options to purchase 7,995 ordinary shares and restricted stock units for 4,305 ordinary shares under the company's 2024 Inducement Stock Option and Incentive Plan. The options have an exercise price of $3.41 per share, matching the closing price on June 3, 2024, a ten-year term, and vest over four years with 25% vesting after the first year and 6.25% vesting quarterly thereafter. The restricted stock units vest at 25% annually over four years.
These grants were made as an inducement for the employees' new roles, complying with Nasdaq Listing Rule 5635(c)(4).
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizumab. Nemvaleukin showed promising pharmacodynamic effects, such as expansion of immune-stimulating CD8+ T cells and NK cells, with minimal expansion of immunosuppressive Tregs, and no new safety issues.
Preliminary data from ARTISTRY-6 cohorts are expected in 2025.
Mural Oncology (Nasdaq: MURA) announced Q1 2024 financial results and a business update. Key highlights include ongoing clinical trials for nemvaleukin alfa in ovarian cancer and melanoma, with readouts expected in 1H 2025. Mural is also evaluating a new, less frequent IV dose of nemvaleukin. Preclinical data on IL-18 and IL-12 therapies were presented in April 2024, with candidate nominations anticipated by year-end.
Financially, Mural reported a net loss of $30.9 million, improved from $46.5 million YoY. Cash reserves stand at $231.7 million, expected to fund operations into Q4 2025. R&D expenses decreased to $26.9 million, while G&A expenses rose to $7.2 million, reflecting standalone public company costs.
Mural Oncology plc announced the granting of non-statutory stock options and restricted stock units to three newly hired employees as inducement material. The stock options have an exercise price of $3.78 per share, with a ten-year term and vesting over four years. The restricted stock units also vest over four years, 25% per year, subject to continued service with the Company.
